The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February ...

BioMarin Pharmaceutical ... development of a gene therapy for hypertrophic cardiomyopathy. The company’s offices in San Rafael and Novato were hit hard, per the WARN, with 67 and 52 layoffs ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

BioMarin Pharmaceutical (BMRN) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research ...

Overall, Q2 2024 was a solid quarter for BioMarin, highlighted by strong product performance and successful financial management. Founded in 1997, BioMarin Pharmaceutical is dedicated to ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...